Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT.; McMullin MF.; Beer PA.; Butt N.; Conneally E.; Duncombe AS.; Green AR.; Mikhaeel G.; Gilleece MH.; Knapper S.; Mead AJ.; Mesa RA.; Sekhar M.; Harrison CN.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT., McMullin MF., Beer PA., Butt N., Conneally E., Duncombe AS., Green AR., Mikhaeel G., Gilleece MH., Knapper S., Mead AJ., Mesa RA., Sekhar M., Harrison CN.

Original publication

DOI

10.1111/bjh.12985

Type

Journal article

Journal

Br J Haematol

Publication Date

11/2014

Volume

167

Pages

418 - 420

Keywords

CALR, JAK inhibition, myeloproliferative disease, Anemia, Humans, Janus Kinase 1, Janus Kinase 2, Maximum Tolerated Dose, Primary Myelofibrosis, Protein Kinase Inhibitors, Pyrazoles, Recurrence, Splenomegaly, Symptom Assessment, Thrombocytopenia